Wang L, Deng M, Ke Q, et al. - Given a non-satisfactory prognosis of intrahepatic cholangiocarcinoma (ICC) following radical resection, and controversy existing about the clinical value of adjuvant therapy (AT), researchers focused on the clinical significance of AT in this multicenter study as well as explored potential patients who would be benefited from AT. From 12 hepatobiliary centers in China, they retrospectively obtained data from ICC patients who had radical resection from December 2012 to December 2015. Depending on if AT was delivered or not, two groups of patients were defined: AT and non-AT groups. The AT group vs the non-AT group experienced longer median overall survival (OS) and disease-free survival (DFS), and AT was proved to be beneficial for both the OS and DFS following 1:2 propensity score matching. A longer median OS was noted in patients receiving postoperative chemotherapy, while a longer median DFS was seen in those receiving postoperative transarterial chemoembolization, as revealed in subgroup analyses stratified by distinct AT strategies. It was inferred that AT affords advantages in ICC cases post-radical resection, particularly in those “middle-risk” patients, as assessed by the established nomogram. However, further investigation and validation are needed to define the exact patient population that is most suitable for AT.